Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
Fifteen months after obtaining approval as the first COVID-19 drug in Japan, Gilead Sciences’ Veklury (remdesivir) is soon to join the NHI price list, which will pave the way for it to be traded under the ordinary distribution channel, according…
To read the full story
Related Article
- Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
REGULATORY
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
- LDP Study Group’s Honebuto Proposal Urges “Freeze” on On-Patent Drug Price Cuts
May 20, 2026
- PMDA Flags Iron Products, ST Combination Drug in Risk Review
May 20, 2026
- MHLW Orders Detailed Report on Tavneos Efficacy Concerns
May 20, 2026
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…